Background
Methods
Patients and clinical procedures
Peripheral blood | Pleural fluid | ||||||
---|---|---|---|---|---|---|---|
Lung cancer | Esophagus cancer | Breast cancer | Pneumonia | Healthy | Lung cancer | Tuberculo pleurisy | |
Age mean (min-max)
| 67(36–89) | 62(39–85) | 51(35–82) | 67(52–83) | 42(25–60) | 66(36–85) | 64(24–85) |
Sex (M/F)
| 31/13 | 5/3 | 0/20 | 8/2 | 8/7 | 9/5 | 12/2 |
Pathologic stage
| |||||||
I
| 8 | 1 | 3 | - | - | - | - |
II
| 8 | 3 | 8 | - | - | - | - |
III
| 14 | 2 | 5 | - | - | 5 | - |
IV
| 14 | 2 | 4 | - | - | 9 | - |
Pathologic Typing
| |||||||
Squ 26 | Squ 6 | - | - | - | Squ 9 | - | |
Ade 16 | Ade 2 | - | - | - | Ade 5 | - | |
LCLC 2 | - | - | - | - | LCLC | - | |
Total number
| 44 | 8 | 20 | 10 | 15 | 14 | 14 |
Patient | Sex | Age (y) | Pathologic Typing | Pathologic Stage | Means of treatment |
---|---|---|---|---|---|
1
| F | 64 | LCLC | II | chemo-therapy for 7 days |
2
| M | 70 | Squ | III | chemo-therapy for 7 days |
3
| M | 70 | Squ | III | chemo-therapy for 7 days |
4
| F | 36 | Squ | III | chemo-therapy for 7 days |
5
| M | 75 | Ad | IV | chemo-therapy for 7 days |
6
| M | 62 | Squ | IV | interventional therapy |
7
| M | 65 | Ad | II | operation |
8
| F | 58 | Squ | IV | chemo-therapy for 7 days |
9
| M | 55 | Squ | III | interventional therapy |
10
| M | 58 | Squ | II | operation |
11
| M | 68 | Ad | I | operation |
12
| M | 61 | Ad | II | operation |
Collection of specimens
RNA extraction and cDNA synthesis
Real-time PCR
Gene | Sequence of selected primer pair (5'-3') | Probe (5'-FAM---TAMRA-3') | Amplicon length (bp) | Ref |
---|---|---|---|---|
LunX
| GCCTCATTGTCTTCTACGGGCTGTT; CTGAGGGCATTTGTCAAGCTTCCT | CAGACCATGGCCCAGTTTGGAGGCCTG | 156 | This work |
CK19
| ACTACAGCCACTACTACACGAC; CAGAGCCTGTTCCGTCTCAAAC | TCTGGCTGCAGATGACTTCCGAACCA | 149 | [17] |
CEA
| AATAACGGGACCTATGCCTGTTT; CCCCAACCAGCACTCCAAT | CATCTGGAACTTCTCCTGGTCTCTCAGCTG | 151 | This work |
VEGF-C
| TTCATTCCATTATTAGACGTTCCCT; GATTATTCCACATGTAATTGGTGGG | CCAGCAACACTACCA CAGTGTCAGGCA | 94 | [18] |
hnRNP A2/B1
| GACTGTGTGGTAATGAGGGATCCT; GCTCAACTACTCTCCCATCAATTGA | CATGGCTGAGGTTGATGCTGCCAT | 133 | This work |
β-actin
| TTGCCGACAGGATGCAGAA; GCCGATCCACACGGAGTACTT | TCATTGCTCCTCCTGAGC | 101 | This work |
Preparation of standard curves
Statistical analysis
Results
Establishment of real-time RT-PCR procedures for the gene markers
LunXmRNA is the most specific gene marker for NSCLC cells in peripheral blood
Group | Total number | Positive Detection Rate | ||||
---|---|---|---|---|---|---|
LunX
|
CK19
|
CEA
|
VEGF-C
|
hnRNP A2/B1
| ||
NSCLC
| 44 | 33/44 (75.0%) | 37/44 (84.1%) | 11/44 (25.0%) | 37/44 (84.1%) | 44/44 (100%) |
Other epithelial cancer
| 28 | 0/28 (0%) | 19/28 (67.9%) | 13/28 (46.4%) | 26/28 (92.9%) | 28/28 (100%) |
Pneumonia
| 10 | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) | 8/10 (80.0%) | 10/10 (100%) |
Healthy
| 15 | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) | 15/15 (100%) |
P value
| < 0.001* | < 0.001* | 0.002* | 0.174* | - | |
< 0.001#
| 0.106#
| 0.060#
| - | - | ||
/ | 0.290$
| < 0.001$
| - | - |
Expression of LunXmRNA in peripheral blood is correlated with the pathologic stage of NSCLC
Clinical factor | Positive cases/total cases |
---|---|
Sex
| |
P value
| 0.461 |
Male | 22/31 (71.0%) |
Female | 11/13 (84.6%) |
Age
| |
P value
| 0.425 |
≤ 60 | 7/11 (63.6%) |
> 60 | 26/33 (78.8%) |
Pathologic Type
| |
P value
| 0.482 |
Squ | 18/26 (69.2%) |
Ade | 13/16 (81.3%) |
LCLC | 2/2 (100%) |
Pathologic Stage
| |
P value
| 0.010 |
I | 3/8 (37.5%) |
II | 5/8 (62.5%) |
III | 11/14 (78.6%) |
IV | 14/14 (100%) |
LunXmRNA is the most specific and sensitive gene marker for NSCLC cells in pleural fluid
Group | Total number | Positive Detection Rate | ||||
---|---|---|---|---|---|---|
LunX
|
CK19
|
CEA
|
VEGF-C
|
hnRNP A2/B1
| ||
NSCLC
| 14 | 13/14 (92.9%) | 14/14 (100%) | 12/14 (85.7%) | 11/14 (78.6%) | 14/14 (100%) |
Tuberculo pleurisy
| 14 | 1/14 (7.1%) | 14/14 (100%) | 6/14 (42.9%) | 9/14 (64.3%) | 14/14 (100%) |
P value
| < 0.001 | - | 0.018 | 0.678 | - |